Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013477

— · cohortMD2

469b8ed3-bb3d-523e-9a27-3ed33128e6c2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortMD2
subtype
cohortMD2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • IL6_JAK_STAT3_SIGNALING+0.510
  • TNFA_SIGNALING_VIA_NFKB+0.510
  • INFLAMMATORY_RESPONSE+0.500
  • INTERFERON_GAMMA_RESPONSE+0.490
  • ALLOGRAFT_REJECTION+0.480
  • INTERFERON_ALPHA_RESPONSE+0.470
  • COMPLEMENT+0.430
  • IL2_STAT5_SIGNALING+0.330
  • MYOGENESIS+0.330
  • KRAS_SIGNALING_UP+0.290

Top 10 suppressed

  • MYC_TARGETS_V1-0.640
  • E2F_TARGETS-0.610
  • MYC_TARGETS_V2-0.610
  • G2M_CHECKPOINT-0.540
  • UNFOLDED_PROTEIN_RESPONSE-0.460
  • GLYCOLYSIS-0.400
  • MTORC1_SIGNALING-0.400
  • PROTEIN_SECRETION-0.390
  • DNA_REPAIR-0.380
  • OXIDATIVE_PHOSPHORYLATION-0.370

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-D8-A73U-01A-11R-A33J-07
breast-umap@18
—D0.941
2SRR8613709
breast-umap@18
—A0.940
3TCGA-56-8623-01A-11R-A28V-07
lung-landscapes@6
—cohortA10.934
4TCGA-A2-A0CO-01A-13R-A22K-07
breast-umap@18
—A0.924
5a802b49c.736d.427c.bcca.8375c4171284
lung-landscapes@6
—cohortA10.911
6TCGA-69-8453-01A-12R-2326-07
lung-landscapes@6
—cohortA10.909
7BS_R244Z0WX
brain-umap@2
pilocytic astrocytoma—0.906
8sclcA055A_S52.txt
lung-landscapes@6
—cohortMD20.902
9MDT-AP-1152
medullo-epn-umap@date-based
MedMedulloblastoma0.901
10TCGA-99-AA5R-01A-11R-A39D-07
lung-landscapes@6
—cohortA10.898

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
IL6_JAK_STAT3_SIGNALING0.510Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.510Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.490Idelalisib— uncovered
ALLOGRAFT_REJECTION0.480Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.470Inavolisib— uncovered
COMPLEMENT0.430Inavolisib— uncovered
IL2_STAT5_SIGNALING0.330Idelalisib— uncovered
MYOGENESIS0.330Inavolisib— uncovered
KRAS_SIGNALING_UP0.290Inavolisib— uncovered
HEDGEHOG_SIGNALING0.250Inavolisib— uncovered
KRAS_SIGNALING_DN0.250Remibrutinib— uncovered
HYPOXIA0.220Idelalisib— uncovered
COAGULATION0.200Binimetinib— uncovered
APICAL_SURFACE0.170Temsirolimus— uncovered
APOPTOSIS0.170Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.160Inavolisib— uncovered
P53_PATHWAY0.150Idelalisib— uncovered
NOTCH_SIGNALING0.130Inavolisib— uncovered
PANCREAS_BETA_CELLS0.130Cobimetinib— uncovered